Matthew M Heeney

List of Publications by Year
in descending order

95 papers	4,476 citations	109321 35 h-index	106344 65 g-index
119 all docs	119 docs citations	119 times ranked	6557 citing authors

#	Article	IF	Citations
1	Standardizing Opioid Prescribing in a Pediatric Hospital: A Quality Improvement Effort. Hospital Pediatrics, 2022, 12, 164-173.	1.3	1
2	Post-Transcriptional Genetic Silencing ofBCL11Ato Treat Sickle Cell Disease. New England Journal of Medicine, 2021, 384, 205-215.	27.0	250
3	A systematic review of ketamine for the management of vasoâ€occlusive pain in sickle cell disease. Pediatric Blood and Cancer, 2021, 68, e28989.	1.5	6
4	SLC25A38 congenital sideroblastic anemia: Phenotypes and genotypes of 31 individuals from 24 families, including 11 novel mutations, and a review of the literature. Human Mutation, 2021, 42, 1367-1383.	2.5	11
5	Belzutifan, a Potent HIF2Î± Inhibitor, in the Pacakâ€“Zhuang Syndrome. New England Journal of Medicine, 2021, 385, 2059-2065.	27.0	36
6	Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia. Trials, 2020, 21, 983.	1.6	11
7	Biochemical and therapeutic effects of Omega-3 fatty acids in sickle cell disease. Complementary Therapies in Medicine, 2020, 52, 102482.	2.7	12
8	Longâ€term hematologic and clinical outcomes of splenectomy in children with hereditary spherocytosis and sickle cell disease. Pediatric Blood and Cancer, 2020, 67, e28290.	1.5	5
9	Mutations in the iron-sulfur cluster biogenesis protein HSCB cause congenital sideroblastic anemia. Journal of Clinical Investigation, 2020, 130, 5245-5256.	8.2	13
10	Study Design and Initial Baseline Characteristics in Solace-Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease. Blood, 2020, 136, 22-24.	1.4	0
11	Clinical and laboratory outcomes following total or partial splenectomy in patients with hereditary spherocytosis. Pediatric Hematology and Oncology, 2019, 36, 382-389.	0.8	4
12	Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3). Contemporary Clinical Trials, 2019, 85, 105835.	1.8	6
13	The effect of iron chelation therapy on overall survival in sickle cell disease and Î²â€thalassemia: A systematic review. American Journal of Hematology, 2018, 93, 943-952.	4.1	47
14	Alu element insertion inPKLRgene as a novel cause of pyruvate kinase deficiency in Middle Eastern patients. Human Mutation, 2018, 39, 389-393.	2.5	4
15	Bronchodilator Use for Acute Chest Syndrome Among Large Pediatric Hospitals in North America. Clinical Pediatrics, 2018, 57, 1630-1637.	0.8	3
16	Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients. Blood Advances, 2018, 2, 2505-2512.	5.2	62
17	Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial). Blood Advances, 2018, 2, 1969-1979.	5.2	29
18	A Scientific Renaissance. Pediatric Clinics of North America, 2018, 65, 445-464.	1.8	1

#	Article	IF	Citations
19	Normalizing hepcidin predicts TMPRSS6 mutation status in patients with chronic iron deficiency. Blood, 2018, 132, 448-452.	1.4	16
20	Flipping the Switch: Initial Results of Genetic Targeting of the Fetal to Adult Globin Switch in Sickle Cell Patients. Blood, 2018, 132, 1023-1023.	1.4	15
21	Optimized Beta-Globin Expression and Enucleation from Induced Red Blood Cells for In Vitro Modeling of Sickle Cell Disease. Blood, 2018, 132, 2359-2359.	1.4	0
22	Neonatal anemia: Revisiting the enigmatic pyknocyte. American Journal of Hematology, 2017, 92, 717-721.	4.1	7
23	Successful utilization of an electronic pain diary in a multinational phase 3 interventional study of pediatric sickle cell anemia. Clinical Trials, 2017, 14, 563-571.	1.6	8
24	Ringed sideroblasts in Î²â€thalassemia. Pediatric Blood and Cancer, 2017, 64, e26324.	1.5	4
25	Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. Blood Advances, 2017, 1, 1645-1649.	5.2	38
26	Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia. Thrombosis and Haemostasis, 2017, 117, 580-588.	3.4	14
27	Newborn Screening for Sickle Cell Disease in Liberia: A Pilot Study. Pediatric Blood and Cancer, 2016, 63, 671-676.	1.5	40
28	Design of the DOVE (Determining Effects of Platelet Inhibition on Vasoâ€Occlusive Events) trial: A global Phase 3 doubleâ€blind, randomized, placeboâ€controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy. Pediatric Blood and Cancer, 2016, 63, 299-305.	1.5	13
29	Labelâ€Free Sickle Cell Disease Diagnosis using a Lowâ€Cost, Handheld Platform. Advanced Materials Technologies, 2016, 1, 1600100.	5.8	47
30	Disease Diagnostics: Labelâ€Free Sickle Cell Disease Diagnosis using a Lowâ€Cost, Handheld Platform (Adv.) Tj ETQq0 0 0 rgBT /Overloc	5.8	0
31	A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia. Blood, 2016, 128, 1913-1917.	1.4	33
32	A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. New England Journal of Medicine, 2016, 374, 625-635.	27.0	117
33	Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemiaâ€"TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet, The, 2016, 387, 661-670.	13.7	375
34	Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia. Journal of Pediatric Surgery, 2016, 51, 122-127.	1.6	39
35	Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype. Journal of Clinical Investigation, 2016, 126, 3868-3878.	8.2	129
36	Variation in Serial TCD Velocity Measurements in the TCD with Transfusions Changing to Hydroxyurea (TWiTCH) Trial. Blood, 2016, 128, 1019-1019.	1.4	4

#	Article	IF	Citations
37	Changes in Extrahepatic Iron Load in Response to Iron Chelation Versus Phlebotomy: Observations from the Twitch Trial. Blood, 2016, 128, 202-202.	1.4	3
38	Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology, 2015, 90, 806-810.	4.1	21
39	Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9. Blood, 2015, 126, 2734-2738.	1.4	78
40	Prasugrel in Children With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2015, 37, 1-9.	0.6	21
41	Clinical outcomes of splenectomy in children: Report of the splenectomy in congenital hemolytic anemia registry. American Journal of Hematology, 2015, 90, 187-192.	4.1	33
42	TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia. Blood, 2015, 126, 3-3.	1.4	19
43	Iron clad: iron homeostasis and the diagnosis of hereditary iron overload. Hematology American Society of Hematology Education Program, 2014, 2014, 202-209.	2.5	5
44	Xâ€linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATAâ€binding site mutations. American Journal of Hematology, 2014, 89, 315-319.	4.1	39
45	Iron Disorders. Hematology/Oncology Clinics of North America, 2014, 28, ix-x.	2.2	0
46	Platelet Activation and Inhibition iN Sickle cell disease (PAINS) study. Platelets, 2014, 25, 27-35.	2.3	47
47	Systemic Corticosteroids in Acute Chest Syndrome: Friend or Foe?. Paediatric Respiratory Reviews, 2014, 15, 24-27.	1.8	17
48	Iron-Refractory Iron Deficiency Anemia (IRIDA). Hematology/Oncology Clinics of North America, 2014, 28, 637-652.	2.2	68
49	Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood, 2014, 124, 891-898.	1.4	75
50	Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood, 2014, 124, 2867-2871.	1.4	162
51	Comparison of Clinical Outcomes Between Adult and Pediatric Patients (pts) with Sickle Cell Disease (SCD): 3-Year (y) Follow-up in a Prospective, Longitudinal, Noninterventional Registry Trial. Blood, 2014, 124, 4890-4890.	1.4	1
52	Bacteremia Risk and Outpatient Management of Febrile Patients With Sickle Cell Disease. Pediatrics, 2013, 131, 1035-1041.	2.1	70
53	Weight Status of Children With Sickle Cell Disease. Pediatrics, 2013, 131, e1168-e1173.	2.1	40
54	A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). Blood, 2013, 122, 112-123.	1.4	101

#	Article	IF	Citations
55	Clinical Outcomes For Patients With Sickle Cell Disease: 24-Month Follow-Up In An Ongoing 3-Year, Prospective, Non-Interventional Registry Trial. Blood, 2013, 122, 988-988.	1.4	7
56	Thirtyâ€day readmission rates following hospitalization for pediatric sickle cell crisis at freestanding children's hospitals: Risk factors and hospital variation. Pediatric Blood and Cancer, 2012, 58, 61-65.	1.5	47
57	Hydroxyurea for the treatment of sickle cell disease: Efficacy, barriers, toxicity, and management in children. Pediatric Blood and Cancer, 2012, 59, 365-371.	1.5	94
58	Platelet Activation and Inhibition in Sickle Cell Disease (PAINS) Study. Blood, 2012, 120, 5147-5147.	1.4	0
59	12-Month Follow-up for Patients with Sickle Cell Disease in an Ongoing 3-Year, Prospective, Non-Interventional Registry Trial. Blood, 2012, 120, 1010-1010.	1.4	0
60	Prasugrel in Children with Sickle Cell Disease: Pharmacokinetic and Pharmacodynamic Characteristics from an Open-Label, Adaptive-Design, Dose-Ranging Study. Blood, 2012, 120, 3213-3213.	1.4	0
61	Longâ€term safety and efficacy of deferasirox (Exjade^{Â®}) for up to 5â€ƒyears in transfusional ironâ€overloaded patients with sickle cell disease. British Journal of Haematology, 2011, 154, 387-397.	2.5	67
62	Loss-of-function and gain-of-function phenotypes of stomatocytosis mutant RhAG F65S. American Journal of Physiology - Cell Physiology, 2011, 301, C1325-C1343.	4.6	24
63	Transition from pediatric to adult care for sickle cell disease: Results of a survey of pediatric providers. American Journal of Hematology, 2011, 86, 512-515.	4.1	52
64	Baseline Characteristics of Patients with Sickle Cell Disease in An Ongoing 5-Year, Prospective, Noninterventional Registry Trial. Blood, 2011, 118, 1060-1060.	1.4	4
65	Definitions of the phenotypic manifestations of sickle cell disease. American Journal of Hematology, 2010, 85, 6-13.	4.1	291
66	Corticosteroids for acute chest syndrome in children with sickle cell disease: Variation in use and association with length of stay and readmission. American Journal of Hematology, 2010, 85, 24-28.	4.1	53
67	Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea. American Journal of Hematology, 2010, 85, 135-137.	4.1	3
68	Encephalopathy From Lead Poisoning Masquerading as a Flu-Like Syndrome in an Autistic Child. Pediatric Emergency Care, 2010, 26, 370-373.	0.9	15
69	Common Variants at 10 Genomic Loci Influence Hemoglobin A1C Levels via Glycemic and Nonglycemic Pathways. Diabetes, 2010, 59, 3229-3239.	0.6	387
70	Hydroxyurea for Children with Sickle Cell Disease. Hematology/Oncology Clinics of North America, 2010, 24, 199-214.	2.2	58
71	High-Throughput Matrix-Assisted Laser Desorption Ionization-Time-of-Flight Mass Spectrometry Method for Quantification of Hepcidin in Human Urine. Analytical Chemistry, 2010, 82, 1551-1555.	6.5	28
72	Long-Term Safety and Efficacy of Deferasirox (ExjadeÂ®) In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years. Blood, 2010, 116, 845-845.	1.4	1

#	Article	IF	Citations
73	Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia: perioperative management and surgical outcome. Neurosurgical Focus, 2009, 26, E10.	2.3	74
74	Clinical practice guideline improves the treatment of sickle cell disease vasoocclusive pain. Pediatric Blood and Cancer, 2009, 52, 369-372.	1.5	34
75	Chronic transfusion practice for children with sickle cell anaemia and stroke. British Journal of Haematology, 2009, 145, 524-528.	2.5	38
76	Clinical and Pathophysiological Aspects of Sickle Cell Anemia. , 2009, , 437-496.		3
77	The Clinical and Genetic Spectrum of TMPRSS6 Mutations Leading to Inappropriate Hepcidin Expression and Iron Refractory Iron Deficiency Anemia (IRIDA).. Blood, 2009, 114, 629-629.	1.4	4
78	Cefepimeâ€induced neutropenia in a teenager. Pediatric Blood and Cancer, 2008, 51, 715-716.	1.5	8
79	Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nature Genetics, 2008, 40, 569-571.	21.4	586
80	Hydroxyurea for Children with Sickle Cell Disease. Pediatric Clinics of North America, 2008, 55, 483-501.	1.8	59
81	Deferasirox (ExjadeÂ®), the Once-Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5-Year Follow-up.. Blood, 2008, 112, 1420-1420.	1.4	10
82	Preventing Stroke Among Children With Sickle Cell Anemia: An Analysis of Strategies That Involve Transcranial Doppler Testing and Chronic Transfusion. Pediatrics, 2007, 120, e1107-e1116.	2.1	30
83	Hemoglobin SE diseaseâ€"A concise review. American Journal of Hematology, 2007, 82, 643-649.	4.1	46
84	Acquired immune cytopenias post-cardiac transplantation respond to rituximab. Pediatric Blood and Cancer, 2007, 48, 339-344.	1.5	32
85	Sickle cell disease caused by Hb S/QuÃ©bec-CHORI: Treatment with hydroxyurea and response. Pediatric Blood and Cancer, 2007, 49, 207-210.	1.5	6
86	Long-Term Efficacy and Safety of Deferasirox (ExjadeÂ®, ICL670), a Once-Daily Oral Iron Chelator, in Patients with Sickle Cell Disease (SCD).. Blood, 2007, 110, 3395-3395.	1.4	5
87	Hemoglobinopathies mimicking Hb S/Î²-thalassemia: Hb S/S with Î±-thalassemia and Hb S/Volga. American Journal of Hematology, 2006, 81, 361-365.	4.1	10
88	Iron homeostasis and inherited iron overload disorders: an overview. Hematology/Oncology Clinics of North America, 2004, 18, 1379-1403.	2.2	44
89	Chemical and Functional Analysis of Hydroxyurea Oral Solutions. Journal of Pediatric Hematology/Oncology, 2004, 26, 179-184.	0.6	37
90	UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia. Translational Research, 2003, 141, 279-282.	2.3	42

#	Article	IF	Citations
91	Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency. Journal of Pediatrics, 2003, 143, 662-665.	1.8	40
92	Increased expression of anti-apoptosis genes in peripheral blood cells from patients with paroxysmal nocturnal hemoglobinuria. Molecular Genetics and Metabolism, 2003, 78, 291-294.	1.1	12
93	A Multistep Model for the Pathogenesis and Evolution of PNH. , 2003, , 41-53.		1
94	Interpretation of Fetal Hemoglobin Only on Newborn Screening for Hemoglobinopathy. Journal of Pediatric Hematology/Oncology, 2002, 24, 499-502.	0.6	5
95	Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study. Blood, 0, , .	1.4	5